BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $50.00 price target on Aardvark Therapeutics Inc (NASDAQ:AARD) on Thursday, representing over 400% upside from the current price of $9.67.
The research firm highlighted the company’s current market capitalization of $234 million, suggesting significant upside potential for investors. According to InvestingPro data, the stock currently trades near its Fair Value, with analysts’ targets ranging from $19 to $50.
Cantor Fitzgerald noted that AARD offers multiple pathways to substantial returns, particularly if both of the company’s programs prove successful.
The firm expressed confidence that Aardvark Therapeutics stock will appreciate as the company approaches data releases expected in 2026.
Cantor Fitzgerald described the investment opportunity as having "a very asymmetric risk-reward profile at current levels," suggesting potential gains outweigh the risks at the current valuation.
In other recent news, Aardvark Therapeutics Inc. has made several announcements that could interest investors. The company reported promising preclinical results for its investigational drug ARD-201, which showed a 19% reduction in body weight in diet-induced obese mice after 30 days. This study also indicated that ARD-201 could enhance weight loss when combined with low-dose tirzepatide compared to high-dose tirzepatide alone. Meanwhile, RBC Capital has adjusted its price target for Aardvark Therapeutics from $20 to $19, citing delays in the company’s Phase III trial for its ’101 drug in Prader-Willi syndrome, now expected to begin in the third quarter of 2026. Despite this, Cantor Fitzgerald has reiterated its Overweight rating and $50 price target, expressing confidence in the company’s Phase 3 study prospects. Additionally, H.C. Wainwright has initiated coverage on Aardvark Therapeutics with a Buy rating and a $40 price target, noting the innovative approach of the company’s lead candidate, ARD-101, in treating obesity and hyperphagic conditions. These developments provide insights into the company’s ongoing research and market perceptions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.